Coronary plaque healing represents a dynamic biological process that substantially influences long-term cardiovascular outcomes, including recurrent acute coronary syndromes and sudden cardiac death. Recent advances in imaging and histopathology have elucidated the interplay between plaque rupture, healing, and stabilization, challenging traditional paradigms of atherosclerotic progression. This article provides a comprehensive review of the mechanisms underpinning coronary plaque healing, its epidemiological significance, and the clinical implications for risk stratification and therapeutic intervention, emphasizing contemporary research and guideline-directed management strategies.
The understanding of atherosclerosis has evolved from a static to a dynamic model, wherein plaque rupture and subsequent healing play critical roles in determining patient outcomes. Plaque healing, defined as the reparative process following subclinical or overt rupture, can lead to plaque stabilization or, conversely, to increased lesion complexity and luminal narrowing. Recognition of the determinants and consequences of plaque healing is essential for optimizing secondary prevention and tailoring individualized therapy in patients with coronary artery disease (CAD).
Coronary artery disease remains the leading cause of morbidity and mortality worldwide, with acute coronary events frequently attributed to plaque rupture or erosion. Epidemiological studies indicate that subclinical plaque disruption and healing are common, occurring in up to 40-60% of asymptomatic individuals with advanced atherosclerosis, as evidenced by autopsy and imaging studies. However, inadequate or maladaptive healing can precipitate recurrent events, contributing to the persistent burden of cardiovascular disease despite advances in pharmacotherapy and revascularization.
Plaque healing is initiated in response to endothelial injury, typically after plaque rupture or erosion, leading to thrombus formation. The healing process involves organization and resorption of thrombus, smooth muscle cell proliferation, extracellular matrix deposition, and re-endothelialization. The resultant neointima can either reinforce structural stability or, when excessive, cause progressive luminal narrowing. The balance between pro-inflammatory and reparative mechanisms determines whether plaque healing results in stabilization or triggers further plaque vulnerability. Characterization of this process has been enhanced by advanced imaging modalities such as optical coherence tomography (OCT), which can detect healed plaque morphologies in vivo.
Traditional cardiovascular risk factors, including hypertension, hyperlipidemia, diabetes mellitus, and smoking, modulate the inflammatory milieu and reparative capacity of the vascular wall, influencing both the frequency and quality of plaque healing. Genetic predispositions, such as polymorphisms in genes regulating inflammation and extracellular matrix turnover, also contribute. Notably, persistent systemic inflammation and impaired endothelial function, as seen in autoimmune disorders or chronic infections, are associated with defective healing and adverse outcomes.
While plaque healing itself is a subclinical process, its clinical manifestations are indirect, often presenting as recurrent angina, acute coronary syndromes, or progressive stable CAD. Repeated cycles of rupture and healing may lead to layered neointima, contributing to incremental stenosis and, in some cases, silent myocardial ischemia. Recognition of such features on imaging or during invasive assessment may guide risk stratification and inform prognosis.
Definitive diagnosis of plaque healing remains challenging due to its subclinical nature. Intravascular imaging modalities particularly OCT have enabled identification of layered neointimal structures, suggestive of healed ruptures, in vivo. Cardiac magnetic resonance imaging and computed tomography angiography may provide adjunctive non-invasive insights but lack the resolution for detailed plaque characterization. Biomarkers of inflammation, endothelial dysfunction, and thrombosis are under investigation for their potential to non-invasively reflect ongoing plaque activity and healing.
Therapeutic strategies focus on modulating the underlying pathobiology of atherosclerosis to promote adaptive healing and prevent destabilization. Statins remain the cornerstone, exerting pleiotropic anti-inflammatory and plaque-stabilizing effects. Antiplatelet agents, particularly dual antiplatelet therapy following acute coronary syndromes, attenuate thrombus burden and may facilitate more organized healing. Intensive glycemic and blood pressure control, lifestyle modification, and aggressive lipid lowering are recommended for secondary prevention. In selected cases, revascularization may be warranted to address hemodynamically significant lesions.
Recent developments include the use of PCSK9 inhibitors and anti-inflammatory agents, such as interleukin-1β antagonists, which have demonstrated additional benefits in reducing recurrent cardiovascular events by targeting residual inflammatory risk. Novel imaging biomarkers are being integrated into risk assessment algorithms, allowing for early identification of high-risk morphologies. Ongoing research into regenerative therapies aims to enhance endothelial repair and promote favorable healing responses, with cell-based therapies and gene editing showing promise in preclinical models.
Current clinical guidelines underscore the importance of aggressive risk factor modification and recommend the use of statins and antiplatelet agents in all patients with established CAD. While there are no specific recommendations regarding plaque healing per se, emerging evidence supports the role of advanced imaging for risk stratification in selected high-risk populations. Personalized medicine approaches, incorporating genetic and biomarker profiling, are anticipated to refine future management strategies.
Understanding the dynamics of coronary plaque healing is critical for improving long-term cardiovascular outcomes. Advances in imaging and therapeutics have illuminated the complex interplay between injury, repair, and clinical events, providing new opportunities for individualized care. Ongoing research will further delineate the mechanisms governing plaque healing and inform the development of targeted interventions to reduce the global burden of coronary artery disease.
1.
A new way to measure suicide risk?
2.
3D virtual staining technology enables non-invasive observation of cancer tissue
3.
Perioperative Nivolumab Boosts EFS Versus Neoadjuvant-Only Nivolumab in NSCLC
4.
I Understand Why Defense Secretary Austin Kept His Prostate Cancer Quiet.
5.
ASCO: Vepdegestrant ups survival in ER+, HER2− advanced breast cancer with ESR1 mutations
1.
Hemophilia B and Gene Therapy: A New Chapter with Etranacogene Dezaparvovec
2.
Driving Impact: Oncology Pharmaceutical Marketing Strategies in the USA
3.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
4.
Predicting Incidental Prostate Cancer in BPH Surgery Patients
5.
How Should We Approach Solid Pseudopapillary Neoplasm of the Pancreas with Hepatic Metastases?
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
2.
The Comprehensive Impact of CDK4/6 Inhibition in HR+/HER2- Metastatic Breast Cancer: Insights from PALOMA-2.
3.
Current Scenario of Cancer- Q&A Session to Close the Gap Part II
4.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
5.
Navigating the Complexities of Ph Negative ALL - Part IX
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation